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Response to the Letters from Hopper and Jenkins and
Foulkes et al.
To the Editor:
These two thoughtful letters (Hopper and Jenkins 1999
[in this issue]; Foulkes et al. 1999 [in this issue]) illustrate
some of the difficulties in drawing conclusions from the
current body of data: even in very large studies, the
number of subjects with breast or ovarian cancer in their
families is small enough that different statistical models
can yield quite different assessments of how likely a per-
son is to be a mutation carrier. When the penetrance
function has been securely established, probably the best
model will be based on genetic inheritance (Berry et al.
1997) rather than on classification and regression trees
(CART) (Breiman et al. 1984), multiple logistic regres-
sion (MLgR), or multiple linear regression (MLnR)
(Wacholder 1986). We elected to explore the data with
CART, to build an “agnostic” model, close to the data,
and added MLnR to try to separate the effects of various
factors (Hartge et al. 1999). We chose not to use MLgR,
to avoid distortion where data are sparse but projections
are clinically relevant. For example, although the figure
in the letter by Hopper et al. (1999) offers a clear qual-
itative depiction of the important factors, we caution
that points on the graph depend heavily on choice of
statistical model.
A word about MLgR: it can seriously misrepresent
the data if the model is misspecified. Although MLgR
is well suited to most problems in cancer epidemiology,
in which the probability of disease developing is low for
all exposure categories, it is not well suited here, where
the probability of being a carrier, given personal and
family history, can range from ∼0% to 20%. Under
MLgR, an effect with an odds ratio of 2 raises the base-
line risk of being a carrier, from 0.1% or 1% to ∼0.2%
or 2% but from 10% or 50% to ∼18% or ∼67%. Only
with relatively high baseline risk would an odds ratio of
2 be an important factor in an individual’s decision-
making process.
The central conclusion from our volunteers remains
that the carrier probabilities in those individuals with
family history of breast or ovarian cancer are substan-
tially lower than indicated by early published estimates.
SHOLOM WACHOLDER AND PATRICIA HARTGE
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